These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30768860)

  • 1. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
    Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
    Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
    Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
    Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results From Phase I Studies Investigating the Dose Linearity of Finerenone Tablets and the Influence of Food or pH-Modifying Comedications on its Pharmacokinetics in Healthy Male Volunteers.
    Heinig R; Nagelschmitz J; Loewen S
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):549-559. PubMed ID: 35612708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
    Cheng Y; Liu L; Xue Y; Zhou S; Li Y
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):579-592. PubMed ID: 35657581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.
    Xin Y; Shao L; Maltzman J; Stefanidis D; Hemenway J; Tarnowski T; Deng W; Silverman JA
    Clin Pharmacol Drug Dev; 2018 Mar; 7(3):277-286. PubMed ID: 29024542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
    Namour F; Desrivot J; Van der Aa A; Harrison P; Tasset C; van't Klooster G
    Drug Metab Lett; 2016; 10(1):38-48. PubMed ID: 26693854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
    Namour F; Fagard L; Van der Aa A; Harrison P; Xin Y; Tasset C
    Br J Clin Pharmacol; 2018 Dec; 84(12):2779-2789. PubMed ID: 30088677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
    Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
    J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.
    Sun W; Klamerus KJ; Yuhas LM; Pawlak S; Plotka A; O'Gorman M; Kirkovsky L; Kosa M; Wang D
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):614-626. PubMed ID: 28430398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
    Shaik N; Hee B; Wei H; LaBadie RR
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
    Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
    J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.
    Anderson K; Nelson CH; Gong Q; Alani M; Tarnowski T; Othman AA
    Clin Pharmacol Drug Dev; 2022 Feb; 11(2):235-245. PubMed ID: 34468080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
    Wu J; Gießmann T; Lang B; Elgadi M; Huang F
    J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
    Xu H; O'Gorman M; Boutros T; Brega N; Kantaridis C; Tan W; Bello A
    J Clin Pharmacol; 2015 Jan; 55(1):104-13. PubMed ID: 24990113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
    Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
    Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects.
    Hsueh CH; Anderson K; Shen G; Yun C; Qin A; Othman AA
    Clin Transl Sci; 2022 Feb; 15(2):361-370. PubMed ID: 34498807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.